Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Lymphoma × BNT162 Vaccine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 1 Lymphoma 1 COVID-19 1

Interventions

pegylated granulocyte colony-stimulating factor 3 entecavir 3 Granulocyte Colony-Stimulating Factor 3 Cyclophosphamide 3 Aprepitant 3 Prednisolone 2 Dexamethasone 2 Brentuximab Vedotin 2 rasburicase 1 prednylidene 1 plerixafor 1 peginterferon alfa-2b 1 pegfilgrastim 1 golimumab 1 fludarabine phosphate 1 fludarabine 1 fluarix 1 ferrous succinate 1 dexamethasone 21-phosphate 1 arexvy 1 abrysvo 1 Zidovudine 1 Water 1 Watchful Waiting 1 Vindesine 1 Vincristine 1 Vinblastine 1 Valproic Acid 1 Urate Oxidase 1 Tropisetron 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05170399 2026-02-05

Vaccine Responses in Patients With B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 4 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡